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Lipid droplets (LD) are organelles present in all cell types,
consisting of a hydrophobic core of triacylglycerols and cho-
lesteryl esters, surrounded by amonolayer of phospholipids and
cholesterol. This work shows that LD biogenesis induced by
serum, by long-chain fatty acids, or the combination of both in
CHO-K1 cells was prevented by phospholipase A2 inhibitors
with a pharmacological profile consistent with the implication
of group IVA cytosolic phospholipase A2 (cPLA2). Knocking
down cPLA2 expression with short interfering RNA was simi-
lar to pharmacological inhibition in terms of enzyme activity
and LD biogenesis. A Chinese hamster ovary cell clone stably
expressing an enhanced green fluorescent protein-cPLA2
fusion protein (EGFP-cPLA2) displayed higher LD occurrence
under basal conditions and upon LD induction. Induction of LD
took place with concurrent phosphorylation of cPLA2 at
Ser505. Transfection of a S505A mutant cPLA2 showed that
phosphorylation at Ser505 is key for enzyme activity and LD for-
mation. cPLA2 contribution to LD biogenesis was not because
of the generation of arachidonic acid, nor was it related to neu-
tral lipid synthesis. cPLA2 inhibition in cells induced to form
LD resulted in the appearance of tubulo-vesicular profiles of the
smooth endoplasmic reticulum, compatible with a role of
cPLA2 in the formation of nascent LD from the endoplasmic
reticulum.
Lipid droplets (LD)5 are organelles present in virtually all cell
types, are formed by a hydrophobic core of triacylglycerols
(TAG) and cholesteryl esters, and are surrounded by a mono-
layer of phospholipids and cholesterol with which a variety of
proteins interact (1–3). LD are considered storage organelles
for energy generation andmembrane-building blocks, although
new roles in protein storage and sorting have been proposed
recently (4, 5). LD are small in most cells (1 m), but a single
cell may contain hundreds of them, contrasting with the big
droplet of adipocytes, the main TAG-storing cells in animals.
LD have received increased interest in the last years, fueled by
their involvement in the pathogenesis of diseases related to fat
storage like obesity, atherosclerosis, and diabetes (6, 7) and pos-
sibly in neurodegenerative disorders like Parkinson (8) and
Alzheimer diseases (9).
Most cells in culture form LD whenever there is lipid avail-
ability from the medium.Whenmaintained in serum-deprived
conditions, cells are practically devoid of LD, which appear
upon addition of complete serum, containing lipoproteins. LD
induced by serum increase in number and size when free fatty
acids are supplemented at nontoxic concentrations (10, 11).
Lipid availability is not the only physiological parameter gov-
erning the occurrence of LD. Stress has been shown in many
instances to induce LD formation; cells reaching confluence
(12, 13), undergoing apoptosis (14, 15), exposed to acidic pH
(10, 16), or engaged in inflammation (17) are some examples. In
fact, cellular stress detected by means of NMR, where mobile
lipids in LD generate specific signals (16, 18), is the basis for
promising imaging techniques for tumor diagnosis and treat-
ment (18, 19).
Over the past years, a number of proteins associated with LD
have been characterized. Among them, the best known is the
perilipin-adipophilin-TIP47 family of proteins, termed collec-
tively PAT (3, 20). Adipophilin, also called adipose differentia-
tion-related protein (ADRP), is a constitutive PAT protein,
which is degraded in the absence of LD, and therefore expres-
sion levels of this protein reflect the mass of stored neutral
lipids (21). Unlike perilipin, which is specific for adipocytes and
steroidogenic cells, ADRP is expressed ubiquitously, and it is
not involved in hormone action (22).
A number of additional proteins have been found associated
with LD fractions, including lipid-metabolizing enzymes. One
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of these is acyl-CoA synthetase (23–25). Inhibition of this
enzyme with triacsin C abolishes the formation of LD in cells
undergoing apoptosis (15), underlining the need for TAG syn-
thesis in the genesis of new LD. Phospholipase D1 has also been
found associated with LD (26) and was shown to promote LD
budding off frommicrosomes in a cell-free system, in amanner
requiring TAG synthesis and an unidentified cytosolic factor
(27). This factor was later identified as ERK2, working appar-
ently downstream of phospholipase D1 to induce dynein asso-
ciation with LD (28). Cytosolic phospholipase A2 (cPLA2), on
the other hand, has also been reported associated to LD (29, 30),
although its implication in their biogenesis is not clear (31).
Key proteins essential for LD generation do not necessarily
have to associate with them, however. In this regard, the
TAG-synthesizing diacylglycerol-acyltransferase or the cho-
lesteryl ester synthesizing acyl-CoA:cholesterol acyltransferase
(ACAT), whose activities promote LDgeneration, are known to
reside in the ER (32–34). Current models support that nascent
LD form in close association with the ER membrane, either
between the membrane leaflets (1, 3) or apposed to the bilayer
(35). Either way, nascent LD should conceivably have a highly
curved geometry, and their formation would involve active
reorganization of the ERphospholipid composition to allow the
formation of amphiphiles favoring this structure. With this
working hypothesis, and taking into account that phospho-
lipases A2 participate in many cellular events involving mem-
brane reorganization and traffic (36), in this study we tested the
possible implication of these fatty acid and lysophospholipid-
generating enzymes in the formation of LD. Phospholipases A2
are a wide group of enzymes that share the capacity to hydro-
lyze glycerophospholipids at the sn-2 position to generate the
corresponding 2-lysophospholipid and a free fatty acid (36–
38). The 15 groups into which PLA2 enzymes have been classi-
fied according to nucleotide and amino acid sequence criteria
include five distinct types of enzymes, namely the secreted
PLA2, the cytosolic PLA2s (cPLA2), the Ca2-independent
PLA2, the platelet-activating factor acetylhydrolases, and the
lysosomal PLA2s (39).
Using flow cytometric analysis of Nile red-stained cells as a
quantitative approach to monitor the occurrence of LD, we
present pharmacological and molecular evidence showing the
involvement of group IVA phospholipase A2 (cPLA2) in the
biogenesis of this organelle.
EXPERIMENTAL PROCEDURES
Materials—[5,6,8,9,11,12,14,15-3H]Arachidonic acid ([3H]AA)
(200 Ci/mmol) was purchased from American Radiolabeled
Chemicals, and [9,10-3H]palmitic acid (49 Ci/mmol) from
Amersham Biosciences. PLA2 inhibitors methylarachidonyl
fluorophosphonate (MAFP) andbromoenol lactone (BEL)were
from Cayman Chemical Co., and arachidonyl trifluoromethyl
ketone (AACOCF3) and pyrrolidine-2 (Py-2, catalog number
525143) were from Calbiochem. Rabbit anti-cPLA2 and anti-
phospho-Ser505 cPLA2 antibodies were from Cell Signaling;
chicken anti-ADRP was from GenWay Biotech; rabbit anti-
GAPDHwas fromAmbion; mouse anti-BiP/GRP78 andmouse
anti-flotillin-1 were from BD Biosciences, and mouse anti--
actin was from Sigma. Sodium oleate, sodium arachidonate,
palmitic acid, tripalmitin, primuline, triacsin C, and Nile red
were from Sigma, and 4,4-difluoro-5-methyl-4-bora-3a,4a-
diaza-s-indacene-3-dodecanoic acid (C1-BODIPY 500/510-
C12) was fromMolecular Probes.
Cells—CHO-K1 cells were cultured in Ham’s F-12 medium
(Sigma), containing 7.5% fetal bovine serum (FBS, Sigma) or
lipoprotein-deficient serum from fetal calf (Sigma), 100
units/ml penicillin (Invitrogen), and 100 g/ml streptomycin
(Invitrogen). Cell passages were made once a week by
trypsinization (Sigma). When indicated, cells (40–70% conflu-
ence) were transfected with 1 g of plasmid/ml using Lipo-
fectamine PlusTM (Invitrogen), following the manufacturer’s
instructions. For stably transfected cells (CHO-cPLA2 and
HEK-cPLA2), 1mg/mlG418 (Invitrogen)was used for selection
and subsequent passages. Other cells were cultured in Dulbec-
co’smodified Eagle’smedium (Sigma), containing 10%FBS, 100
units/ml penicillin, and 100 g/ml streptomycin. These cell
types were human embryo kidney (HEK) cells and HEK cells
stably expressing EGFP-cPLA2 (40, 41), primary astrocytes
from rat cerebral cortex (42), human neuroblastoma SH-5YSY
(ECACC number 94030304), and rat smooth muscle embry-
onic aorta A7r5 (ECACC number 86050803) cells, from the
EuropeanCollection of Cell Cultures, and human chronic B cell
leukemia EHEB cells (DSMZ number ACC 67) from the Ger-
man Collection of Microorganisms and Cell Cultures.
Nile Red Staining and Fluorescence Microscopy—Cells cul-
tured on glass bottom culture dishes were washed with phos-
phate-buffered saline (PBS, Sigma), fixed with 3% paraformal-
dehyde for 10 min, and washed twice with PBS. Cells were
overlaidwith 0.5ml of PBS, towhich 2.5l of a stock solution of
Nile red in acetone (0.2 mg/ml) was added, so that the final
concentrations of Nile red and acetone were 1 g/ml and 0.5%,
respectively. Samples were kept in the dark until photographed
in a Leica Qwin 500 microscope with a Leica DC200 camera,
using the Leica DCviewer 3.2.0.0 software.
Confocal Microscopy—Serum-starved CHO-K1 cells were
treated for 6 h with 7.5% FBS and 1 MC1-BODIPY-C12, either
in the absence or presence of MAFP. After two washes with
PBS, cells were fixed as outlined above and photographed in a
Leica TCS SP2 AOBS confocal microscope. To monitor re-lo-
cation of EGFP-cPLA2, serum-deprived CHO-PLA2 cells were
treated with 7.5% FBS for 1 h, and then 5 M ionomycin was
added. Images were acquired every 60 s.
Image Analysis—Analysis of LD in photomicrographs was
performedwith ImageJ 1.38x public software (Wayne Rasband,
National Institutes of Health; rsb.info.nih.gov), as illustrated in
supplemental Fig. S3.
Electron Microscopy—Cells were rinsed twice with 0.1 M
phosphate-buffered saline (PBS), pH 7.4, and fixed with PBS
containing 2.5% (v/v) glutaraldehyde and 2% (v/v) paraformal-
dehyde for 2 h at 4 °C. After four 10-min washes in PBS, cells
were postfixed with 1% osmium tetroxide in PBS for 2 h at 4 °C,
washed in PBS, dehydrated through an ascending series of ace-
tone concentrations up to 100%, and included in EPON resin.
Micrographs were taken with a JEOL JEM-2011 electron
microscope equipped with a CCD GATAN 794 MSC 600HP
camera.
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Flow Cytometry—After each treatment, cells were harvested,
washed with PBS, and fixed with 3% paraformaldehyde for 10
min. After two PBS washes, they were resuspended in 1 ml of
PBS, to which 5 l of the stock solution of Nile red was added
(final concentration, 1 g/ml). Samples were kept at least 45
min in the dark to attain equilibriumwith the dye. Analysis was
carried out with a Cytomics FC 500 (Beckman Coulter)
equipped with an argon laser (488 nm), in the FL1 channel
(505–545 nm), with the photomultiplier set at 600 V and a gain
value of 1. After gating out cellular debris, 30,000 events where
taken in all the assays. Given the high avidity of the dye for
plastic tubing, and to avoid interference with other flow cytom-
etry applications, a specific pickup tubewas usedwheneverNile
red-stained samples were analyzed.
[3H]Arachidonic Release—Serum-starved cells, seeded in
24-well plates, were labeled with 0.25 Ci of [3H]AA (0.5 Ci/
ml) for 24 h, then washed once with PBS, incubated for 5 min
with Ham’s F-12 supplemented with 0.5 mg/ml albumin, and
washed twicemore with PBS (41). Radioactivity in the last wash
was subtracted from released [3H]AA over the stimulation
period. Cells were then treated as described in each experiment.
At the end of the treatments, culture media were taken, centri-
fuged, and counted. Cell monolayers were detached with ice-
cold PBS containing 1% Triton X-100 and also counted for
radioactivity. Stimulated [3H]AA release represents a balance
between what has been liberated to the medium and what has
been incorporated into the cells.
Cellular Fractionation—Harvested cells were washed with
PBS and homogenizedwith a 10-s sonication in 0.6ml of 10mM
Tris-HCl, containing 0.25 M sucrose, 1mMEDTA, and protease
inhibitors. The homogenate was centrifuged 1 h at 20,000 g.
The supernatantwas kept aside, and the pellet was resuspended
in 0.6ml of homogenization buffer. 0.2ml of each fraction were
used for Western blot of marker proteins, and lipids were
extracted from the remaining volume.
Thin Layer Chromatography—Cells were harvested on ice,
washed with 1 ml of PBS, and pelleted for extraction of lipids
(43). To separate the major lipid species, 0.2-ml aliquots of the
chloroform phases were evaporated under vacuum, resus-
pended in 15 l of chloroform/methanol (3:1, v/v), and spotted
onto Silica Gel G thin layer chromatography plates (Merck),
which were developed in hexane/diethyl ether/acetic acid (70:
30:1, v/v), and stainedwith iodine vapor orwith primuline spray
(5 mg of primuline in 100 ml of acetone/water (80:20, v/v)).
Identification of phospholipids, diacylglycerol, cholesterol, free
fatty acids, TAG, and cholesteryl esters was made by co-migra-
tionwith authentic standards.Quantification of radioactive lip-
ids was done by scraping into vials the silica gel from regions
corresponding to migration of the standards. Primuline-
stained TAG was quantified by densitometry after acquiring
images under UV (340 nm) light.
Immunoblots—Cells were lysed with 62.5 mM Tris-HCl
buffer, pH 6.8, containing 2% SDS, 10% glycerol, 50 mM dithio-
threitol, and 0.01% bromphenol blue, and around 20 g of pro-
tein were separated by standard 10% SDS-PAGE and trans-
ferred to nitrocellulose membranes. Primary (1:1,000) and
secondary antibodies (1:5,000) were diluted in 25 mM Tris-HCl
buffer, pH 7.4, containing 140mMNaCl, 0.5% defatted drymilk,
and 0.1% Tween 20, with the exception of ADRP antibody,
which was blocked with 0.5% bovine serum albumin. Mem-
branes were developed using ECL detection reagents from
Amersham Biosciences and visualized using a GeneGenome
HR chemiluminescence detection system coupled to a CCD
camera.
Constructs—The construct codifying for the expression of a
fusion protein containing N-terminal enhanced green fluores-
cent protein (EGFP) followed by the entire sequence of the
human cPLA2 (EGFP-cPLA2) was described elsewhere (40,
41). To obtain the construct for EGFP-S505A-cPLA2, wild-type
cPLA2 was mutagenized by replacing Ser505 with Ala, using the
QuikChange XL site-directed mutagenesis kit (Stratagene) and
the oligonucleotides 5-CAA TAC ATC TTA TCC ACT GGC
GCC TTT GAG TGA CTT-3 (forward) and 5-GCA AAG
TCA CTC AAA GGC GCC AGT GGA TAA GAT GTA-3
(reverse). Mutagenesis was confirmed by sequencing.
siRNATransfection—Two pre-designed siRNAs (Gene Link)
directed against human cPLA2were used as follows: sense and
antisense PLA2G4A2-(2424) (siRNA1), and sense and anti-
sense PLA2G4A1-(1329) (siRNA2). Cells were transfected at
60% confluence by adding to each 35-mm culture well 1 ml of
Opti-MEM (Invitrogen) containing 1.5 l of the stock siRNA
solution (20 M) and 5 l of Lipofectamine PlusTM (1 mg/ml).
After 5 h, 1 ml of Ham’s F-12medium containing 7.5% FBS was
added, and the cells were incubated for 48 h and then changed
to serum-free medium during 24 h prior to stimulation with
FBS. For the assays of cPLA2 activity, prelabeling with [3H]AA
was done during these last 24 h. In some experiments, a siRNA
directed against humanGAPDH (Ambion) was used as control.
Calcium Imaging—Cells grown onto polylysine-coated cov-
erslips were incubated with the calcium indicator Fura-2/AM
at 4 M in Krebs buffer of the following composition (in mM):
119 NaCl, 4.75 KCl, 5 NaHCO3, 1.2 MgSO4, 1.18 KH2PO4, 1.3
CaCl2, 20 Hepes, and 5 glucose, pH 7.4. After 1 h, cells were
washed and coverslips mounted in a static chamber on an
inverted Nikon TE2000U microscope of a conventional epif-
luorescence system. Cells were excited alternatively at 340 and
380 nm, and emission light was collected at 510 nm every 10 s
using a 12 bit-CCD ERG ORCA Hamamatsu camera. Ratio
image of cells was analyzed using the Metafluor software (Uni-
versal Imaging). 14–20 cells were analyzed in each experiment.
Statistical Analysis—Data analysis was carried out with
Prism software (GraphPad). Responses among different treat-
ments were analyzed with one-way analysis of variance fol-
lowed by Bonferroni’s multiple comparison test.
RESULTS
Flow Cytometry as a Tool to Quantify LD—Our aim was to
study LD dynamics under regular culture conditions, avoiding
whenever possible the induction of cellular stress, which has
been shown to induce the formation of LD. It has long been
known that cells accumulate LD from serum lipoproteins (10),
and therefore our first goal was to set an experimental system
with the highest variation in LD content among quiescent,
serum-starved cells and cells treatedwith FBS. For this purpose,
we examined various cell models for the occurrence of LD,
which we labeled with the lipophilic dye Nile red. To quantify
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this, we monitored initially the percentage of cells containing
two or more LD (13) at various days after plating in serum-
containing medium and after serumwithdrawal (supplemental
Fig. S1). Using this criterion, 100% CHO-K1 cells cultured in
FBS-containing medium were LD-positive from day 1 onward.
Serum deprivation at day 2 reduced LD-containing cells after
24 h to only 10–15%. HeLa cells and primary astrocytes also
reduced LD content after serum deprivation but to a lesser
extent. We therefore decided to explore deeper the mecha-
nisms of LD formation when serum-deprived CHO-K1 cells
were challenged with 7.5% FBS.
The criterion to consider LD-positive every cell containing
two or more LD may be convenient as a first approach, but it
does not discriminate cells containing more than two droplets
or cells containing LD of different sizes. This is the case when
comparing LD content in cells treated with FBS in the presence
or absence of 100 M sodium oleate, as shown in Fig. 1. Serum-
deprived cells were virtually devoid of LD (Fig. 1A), whereas a
6-h treatment with 7.5% FBS induced LD inmost cells (Fig. 1B).
The same is true when LD formation was induced with FBS
togetherwith an overload of exogenous sodiumoleate (Fig. 1C).
However, the overall occurrence of LD was higher with the
latter treatment, as evidenced by simple visual inspection or by
the level of expression of ADRP (Fig. 1D). These two conditions
were discriminated after image analysis of the photomicro-
graphs (Fig. 1E; see also supplement Fig. S2) or after indirect
quantification with cell cytometry (Fig. 1, F and G). Compared
with serum-starved cells, the right shifts of the fluorescence
profiles, shown in Fig. 1F, indicate a stronger signal in the pres-
ence of oleate than in its absence, and this can be quantified
after the median value of each distribution of events (Fig. 1G).
LD induction by both treatments was abolished in the presence
of the acyl-CoA synthetase inhibitor triacsin C, as evidenced by
microscopic examination (not shown) and the left shift of the
fluorescence distributions (Fig. 1, H and I), which were similar
to those from serum-starved cells. Furthermore, the time
course of LD formation after addition of FBS was easily moni-
tored by flow cytometry, with an increase in the fluorescent
signal up to 16 h (supplemental Fig. S3, A and D). Oleate in the
presence of FBS induced a faster increase of the Nile red-asso-
ciated fluorescence (supplemental Fig. S3, B and D). As
expected, treatment with lipoprotein-deficient serum did not
induce LD, quantified either by microscopic examination (not
shown) or by flow cytometry (supplemental Fig. S3, C and D).
Overall, the remarkable reproducibility of the data and the high
number of cells that can be analyzed in a single fluorescence
profile (30,000 events were acquired for each sample) show that
flow cytometric analysis of Nile red-stained cells is a very accu-
rate method for the indirect quantification of LD.
Inhibition of cPLA2 Abolishes the Release of Arachidonate but
Not Palmitate from Cells Treated with FBS—To determine the
possible implication of PLA2 in the mechanisms of LD forma-
tion,we first looked for fatty acid-releasing activities induced by
FBS. Exposure of serum-starved CHO-K1 cells to FBS induced
the release of [3H]AA and [3H]palmitic acid, but only release of
[3H]AA was inhibited by a 10 M concentration of the cPLA2
inhibitormethyl arachidonyl fluorophosphonate (MAFP) (sup-
plemental Fig. S4, A and B). 10 M arachidonyl trifluoromethyl
ketone (AACOCF3) and 1 M pyrrolidine-2 (Py-2), but not 10
MBEL, also inhibited [3H]AA release (supplemental Fig. S4C).
Unlike complete FBS, lipoprotein-deficient serumdid not stim-
ulate the release of [3H]AA (not shown). Although AACOCF3
and MAFP inhibit cPLA2 and iPLA2 (groups IVA and VI,
respectively) (44), Py-2 is relatively specific for group IVA PLA2
(cPLA2) (45), although it has been shown that it also inhibits
group IVF (cPLA2) (46). In contrast, BEL is an inhibitor spe-
cific for iPLA2 (group VI) (44). These results suggest that FBS
stimulates cPLA2.
Inhibition of PLA2 Precludes FBS-stimulated Formation of
LD—To test pharmacologically the implication of cPLA2 in
the appearance of LD, we designed experiments to show inhib-
itor concentration-effect relationships for the reversal of LD
induction by FBS (Fig. 2). For this purpose, we treated serum-
starved cells (see Fig. 1A) with FBS in the presence of inhibitors
and measured LD by flow cytometry. AACOCF3 (Fig. 2, A and
B), MAFP (Fig. 2, C and D), and Py-2 (Fig. 2, E and F) inhibited
the formation of LD in a concentration-dependent fashion that
allowed the calculation of IC50 values (0.98, 0.29, and 0.11 M,
respectively). 10MBEL had no effect in the formation of LD as
assessed by flow cytometry (not shown) or microscopic inspec-
tion (compare micrographs G and H in Fig. 2 for the effects of
BEL andMAFP, respectively). Furthermore,MAFPbut not BEL
inhibited the increase of ADRP induced by FBS (Fig. 2I). We
found no evidence of cytotoxicity because of 24-h treatments
with 10 M concentrations of AACOCF3 and MAFP or 1 M
Py-2 either in serum-starved cells, in the presence of 7.5% FBS,
or with 7.5% FBS plus 100 M oleate, as assessed by a 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduc-
tion assay (not shown).
Silenced Expression of cPLA2 Inhibits the Formation of LD—
Nonpharmacological inhibition cPLA2 was undertaken by
silenced expression of the enzyme. For this purpose, we trans-
fected two different siRNAs and, after serum deprivation,
looked for cPLA2 protein and activity and LD formation in
response to FBS (Fig. 3). Of the two siRNAs, only one (siRNA1)
reduced the expression of cPLA2 and also of ADRP (Fig. 3A).
Silenced expression paralleled the reduction in [3H]AA release
(Fig. 3B) and LD occurrence (Fig. 3,C andD) to levels similar to
FIGURE1. Indirect LDquantificationby flowcytometry. Serum-starvedCHO-K1 cellswere kept untreated (A) or treated for 6hwithmediumcontaining7.5%
FBS alone (B) or in combination with 100M sodium oleate (C). Scale bar represents 10m. AWestern blot of ADRP in total cellular extracts under these three
conditions is shown in D. After fixation, cells were stained with Nile red, and the presence of LD was quantified either by ImageJ analysis of total LD area in 10
micrographs from each condition (E) or by flow cytometry (F and G). F shows the distributions of 30,000 events for each condition in the FL1 channel, in linear
scale, obtained in a representative experiment. Fluorescence intensities, quantified as the median value of each event distribution, are presented in G, which
showsmeans S.E. of themedian obtained in three independent experiments.H and I, cells were treated as in F andG, but in the absence or presence of 5M
triacsin C (TRC). H shows the distribution profiles of 10,000 events; and I shows the means  S.E. of the median values in three experiments. *, p  0.001
compared with control in the absence of FBS and oleate; #, p 0.001 compared with FBS alone.
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those in serum-starved cells or in
FBS-stimulated cells in the presence
of MAFP. These results, together
with the pharmacological approach,
are consistent with the implication
of cPLA2 in LD biogenesis.
Overexpression of cPLA2 En-
hances the Occurrence of LD—Addi-
tional evidence, summarized in Fig.
4, came from a CHO-K1-derived
cell clone (CHO-cPLA2) stably
expressing an EGFP-cPLA2 fusion
protein (40, 41). As shown in Fig. 4A
(left), the bigger size of the trans-
fected protein, with an apparent
molecular mass of 135 kDa, made it
easily discriminated from the
endogenous enzyme, with an appar-
ent molecular mass of 105 kDa.
When maintained in medium con-
taining 7.5% FBS, this clone
expressed a higher level of ADRP
than the parental line (Fig. 4A,
right). In addition to calcium at the
micromolar level, cPLA2 is re-
gulated positively by phosphoryla-
tion at Ser505 (38). In agreement
with this, phospho-Ser505-cPLA2
increased as starved CHO-K1 cells
were exposed to FBS (Fig. 4B).
Unlike the phosphorylated endoge-
nous enzyme, unambiguous detec-
tion of EGFP-cPLA2 phosphoryla-
ted at Ser505 in CHO-cPLA2 cells
was somewhat hampered by a non-
specific band of the same size also
appearing in CHO-K1 cells. Despite
this, it is apparent that serum-
starved CHO-cPLA2 cells main-
tained a higher level of phosphoryl-
ated enzyme than CHO-K1 cells,
and also that phosphorylation of
both endogenous cPLA2 and EGFP-
cPLA2 increased in CHO-cPLA2
cells in response to FBS. Impor-
tantly, FBS did not alter the nonspe-
cific band present in CHO-K1
lysates. In close agreement with
phosphorylation results, release of
radioactivity from [3H]AA-prela-
beledCHO-cPLA2 cells was 2.5-fold
that of CHO-K1 cells under serum-
starved conditions and 2.2-fold after
stimulationwith FBS, and this effect
was sensitive to MAFP inhibition
(Fig. 4C). Regarding LD occurrence,
CHO-cPLA2 cells closely paralleled
data obtained in [3H]AA release
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experiments; under serum-starved conditions, the median of
the fluorescence distribution of CHO-cPLA2 cells was 1.8-fold
that of CHO-K1 cells and 1.7-fold after stimulation with FBS
(Fig. 4, D and E). Again, the increased occurrence of LD in
CHO-cPLA2 cells, both under serum-starved and FBS-stimu-
lated conditions, which is illustrated in Fig. 4, F and G, was
inhibited byMAFP (Fig. 4E). Taken together, these results show
that overexpression of cPLA2 enhances the occurrence of LD.
cPLA2 Phosphorylation at Ser505 Is Required for the Forma-
tion of LD—To determine whether phosphorylation of cPLA2
at Ser505 is relevant for enzyme activity and LD biogenesis, we
transiently transfected Chinese hamster ovary K1 cells with an
EGFP-cPLA2 fusion protein with a S505A mutation, with
EGFP-cPLA2, or with EGFP alone (Fig. 5). Transfection was
monitored by fluorescence microscopy (not shown) and by
Western blot (Fig. 5A). After a 6-h stimulation with FBS,
cPLA2 was phosphorylated at
Ser505 but S505A-cPLA2 was not.
Furthermore, AA release as stimu-
lated by FBS in cells transfectedwith
S505A-cPLA2 was similar to that
in cells transfected with EGFP
alone, and significantly lower than
in EGFP-cPLA2-transfected cells
(Fig. 5B). Likewise, LD occurrence
in cells transfected with EGFP-
S505A-cPLA2 was the same as that
in cells transfected with EGFP
alone and significantly lower than
in EGFP-cPLA2-transfected cells
(Fig. 5,C andD). These results show
a key role of Ser505 phosphorylation
of cPLA2 for enzyme activation
and LD biogenesis. This phospho-
rylation site has been shown to play
an important role in regulating
enzyme activity under conditions of
transient increase of the intracellu-
lar calcium concentrations, enhanc-
ing the membrane affinity of
cPLA2 (46, 47). Consistent with
this, FBS induced a relatively small
and transient (5–7 min) increase in
cytosolic calcium, clearly different
from the robust signal elicited by
ionomycin (supplemental Fig. S5).
In agreement with these different
calcium responses, FBS did not
induce any apparent change in the
cellular distribution of EGFP-
cPLA2, in contrast with the translo-
cation to nuclear and perinuclear
membranes induced by ionomycin (supplemental Fig. S5).
cPLA2 Is Not Involved in the Synthesis of Neutral Lipids dur-
ing LD Biogenesis—To test whether the role of cPLA2 in the
biogenesis of LD is to provide AA for neutral lipid synthesis
(TAG and cholesteryl esters), we assayed the ability of exoge-
nous AA to induce LD in serum-starved cells and also to stim-
ulate cPLA2 (Fig. 6). AA at a 10M concentration induced the
increase of ADRP, and also the phosphorylation of cPLA2 at
Ser505 (Fig. 6A). Higher concentrations (100 M) of the fatty
acid were toxic in the absence of FBS, resulting in 60% reduc-
tion in cell viability over 6 h (data not shown). Exogenous AA
(10 M) also stimulated the release of [3H]AA (Fig. 6B), in an
MAFP-sensitive manner, to a level similar to that attained with
7.5% FBS, and this response was stronger at 100 M AA in the
presence of 7.5% FBS. Results on cPLA2 activity were mir-
FIGURE 2. cPLA2 inhibitors prevent the appearance of FBS-induced LD. Serum-deprived CHO-K1 cells were treated for 16 h with 7.5% FBS in the presence
of different concentrations of the indicated cPLA2 inhibitors, and LDwere quantified by flow cytometry. A, C, and E show event distributions in representative
experiments. B, D, and F presentmeans S.E., obtained in three independent experiments, of themedian values of the event distributions for each condition,
expressedas the increase above the control in theabsenceof FBS,whichaveraged40513 (n9).GandH showNile red-stainedcells treated for 6hwith7.5%
FBS in the presence of 10MBEL orMAFP, respectively. Scale bar, 10m. I shows aWestern blot of ADRP from serum-starved cells or cells treatedwith FBS and
in the absence or presence of BEL or MAFP. *, significantly different (p  0.01) from serum-starved conditions; #, significantly different (p  0.01) from
serum-induced LD.
FIGURE 3. Silencing the expression of cPLA2 also prevents the appearance of LD. CHO-K1 cells were
transfected with two cPLA2-siRNA sequences as described under “Experimental Procedures,” resulting in
silenced expression of cPLA2with siRNA(1) but not with siRNA(2), (A). Silenced expression with siRNA(1) was
in line with decreased cPLA2 activity, similar to the inhibition of control cells with MAFP (B), and decreased
capacity of FBS to induce LD (C and D). B represents means  S.E. of three independent experiments with
triplicatedeterminations.Data inD aremeans S.E. of themedian values of three eventdistributionsobtained
in independent experiments. *, significantly different (p 0.05) from serum-starved conditions.
Group IVA PLA2 and Lipid Droplet Biogenesis
OCTOBER 10, 2008•VOLUME 283•NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 27375
Group IVA PLA2 and Lipid Droplet Biogenesis
27376 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 41•OCTOBER 10, 2008
rored by the occurrence of LD (Fig. 6, C and D); AA alone at
subtoxic concentrations (10M) induced the appearance of LD,
and this was prevented byMAFP. These results show that exog-
enousAA is sufficient to induce the formation of LD, againwith
a mechanism involving cPLA2 activity and, importantly, that
effects of cPLA2 inhibition on LD biogenesis cannot be over-
come by supplementation of its product. Identical experiments
were conducted using sodium oleate (supplemental Fig. S6) or
palmitic acid (not shown) as exogenous fatty acids; in the
absence of FBS, both fatty acids at 10 M were not toxic,
induced ADRP expression, cPLA2 phosphorylation and activ-
ity, and LD biogenesis. As with AA, 100 M oleate or palmitic
were toxic in the absence of FBS, but in its presence they
induced cPLA2 activity and LD appearance in an MAFP-sen-
sitive manner. Furthermore, enzyme activity and LD occur-
rence after treatment with 10 M
oleate decreased to basal levels after
silencing enzyme expression with
siRNA(1) (supplemental Fig. S6, E
and F), and the same results were
obtained with 10 M AA or palmi-
tate (data not shown). Essentially
identical results regarding LD
occurrence (supplemental Fig. S6G)
were obtained when 10 M oleate
was supplied in amore physiological
way, after complexion with bovine
serum albumin at a ratio of 6:1 (48).
Taken together, these results show
that fatty acid-induced formation of
LD is a cPLA2-dependent process
and suggest that the enzymemay be
necessary for roles other than gen-
erating fatty acids for TAG and cho-
lesteryl ester synthesis. This was
confirmedby following the distribu-
tion of [3H]AA among the main
neutral lipids after a 24-h prelabel-
ing period, followed by a 6-h stimu-
lation with FBS to induce LD (Fig.
6E); about 17,000 dpm were
released to the medium in an
MAFP-sensitive manner, indicative
of cPLA2 stimulation. However,
barely 70 dpm were incorporated
into TAG and even less into cho-
lesteryl esters under these LD-in-
ducing conditions. The results show
that forming LD content is not a
major fate of AA released by cPLA2.
cPLA2 Is Not Involved in the Channeling of Extracellular
Fatty Acids into Neutral Lipids—Adifferent possibility we con-
sidered is that cPLA2 could be required for the channeling of
fatty acids from the medium into the synthesis of TAG and
cholesteryl esters. To address this, we pulsed cells with [3H]AA
in the absence of FBSduring 6 h andmeasured its incorporation
into the major cellular lipid species, using three different AA
concentrations as follows: 10 nM (Fig. 7A), which is a concen-
tration of the fatty acid far below that required to induce LD; 1
M (Fig. 7B), which still is not enough for LD induction (not
shown); and 10 M (Fig. 7C), which stimulates cPLA2 phos-
phorylation and activity, ADRP expression, and LDoccurrence,
as shown in Fig. 6. In all situations, [3H]AA was incorporated
FIGURE4.Overexpressionof cPLA2enhances theoccurrenceof LD.ACHO-K1-derived clone stably expressing EGFP-cPLA2 (A andB) displayedenhanced
basal (under serum-starved conditions) and FBS-induced cPLA2 activity (C) and enhanced LD occurrence under serum-starved or FBS-stimulated conditions
(D–G). A and B show Western blots of cell lysates from CHO-K1 and CHO-cPLA2 cells against cPLA2 (A) or phospho-Ser
505-cPLA2 (B), the former from cells in
mediumcontaining 7.5%FBS, and the latter from serum-starvedor FBS-treated cells. GAPDH (A) or actin (B) was used as loading controls.C showsmeans S.E.
of three independent experiments with triplicate determinations and represents radioactivity released into the medium from [3H]AA-prelabeled CHO-K1 or
CHO-cPLA2 cells during a6-h stimulationwith 7.5%FBS, andwithorwithout 20MMAFP.D and E showLD indirect quantification inCHO-K1orCHO-cPLA2 cells
treated for 6 h with 7.5% FBS and with or without 20 M MAFP and represent event distributions in a representative experiment (D) or means S.E. of the
median values of the event distributions (increase above control) in three independent experiments, respectively. F and G show LD in CHO-cPLA2 cells
maintained in serum-freemedium or inmedium containing 7.5% FBS, respectively. Note the high occurrence of LD in serum-starved cells. Scale bar, 10m. *,
significantly different (p  0.01) from serum-starved conditions; #, significantly different (p  0.01) from serum-induced LD in CHO-cPLA2; $, significantly
different (p 0.05) from serum-starved CHO-cPLA2.
FIGURE 5. Phosphorylation of cPLA2 in Ser
505 is required for the formation of LD. CHO-K1 cells were
transiently transfected with plasmids encoding EGFP alone, EGFP-cPLA2, or EGFP-S505A-cPLA2, and main-
tained in FBS (A) or deprived from serum for 24 h prior to stimulation with FBS for 6 h (B–D). A,Western blot of
total cPLA2, phospho-Ser
505-cPLA2, and GAPDH as a loading control. B, AA release from cells containing EGFP
alone, EGFP-cPLA2, or EGFP-S505A-PLA2over a 6-h stimulationwith FBS.C andD, indirect quantificationof lipid
droplets after 6 h with FBS. Results are representative of three experiments (A and C) or means S.E. of three
independent experiments (B and D). *, significantly different (p 0.01) from EGFP-transfected cells.
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mainly into phospholipids, and this was inhibited by MAFP to
some extent, probably because of the housekeeping activity of
MAFP-sensitive iPLA2, which is involved in an ongoing deacy-
lation-reacylation cycle for phospholipid remodeling (49). It is
noticeable, however, that at all three concentrations of the fatty
acid, regardless of whether they were enough to induce LD
formation (Fig. 7C) or not (Fig. 7, A and B), the inhibition of
cPLA2 did not decrease [3H]AA incorporation into TAG or
cholesteryl esters. Rather, there was a tendency, although it did
not reach significance, of increased TAG labeling in the pres-
ence of MAFP. These results suggest that, during LD biogene-
sis, cPLA2 is necessary at a step
beyond the synthesis of neutral lip-
ids. This was confirmed after meas-
uring total TAG content in serum-
starved cells and in cells treated for
6 h with FBS plus 100 M oleate,
either in the absence or presence of
MAFP (Fig. 7,D andE). Induction of
LD with FBS plus oleate took place
with an increase in TAG from 5.6
0.6 to 9.3 0.3g/2 105 cells, and
itwas not altered by inhibition of LD
biogenesis by MAFP (9.5  1.1
g/2  105 cells). These results
show that cPLA2 is not involved in
the channeling of extracellular fatty
acids into neutral lipids during LD
biogenesis.
Inhibition of cPLA2 under LD-
forming Conditions Alters ER
Structure—As cPLA2 did not
affect neutral lipid synthesis, it
could be required at a later step to
allow LD formation from the ER. To
test this, wemonitored the distribu-
tion of the fluorescent fatty acid
C1-BODIPY-C12 inside the cells
during a 6-h stimulation with FBS.
As shown in Fig. 8, A–D, the tracer
incorporated mainly into LD-like
structures but was retained in intra-
cellular membranes in the presence
of MAFP. An ultrastructural study
revealed that treatment with FBS
together with 100 M oleate during
10 h induced massive appearance of
LD and the development of smooth
ER, often in close apposition to LD
(Fig. 8, E and F; see also supplemen-
tal Fig. S7, E and F). When LD for-
mation was partially inhibited by
MAFP (see supplemental Fig. S6, C
and D, showing that LD are not
totally abolished after this overload
of fatty acid), there was a marked
development of tubulovesicular
structures, probably related to the
smooth ER, which filled practically all the cell (Fig. 8,G andH; see
also supplemental Fig. S7G), eventually forming aberrant mem-
brane stacks (supplemental Fig. S7H). In contrast, serum-starved
cells containednoLD, awell defined roughER, andapoorly devel-
oped smooth ER (supplemental Fig. S7, A and B). Treatment of
serum-starved cells with MAFP revealed no alterations in the
intracellular membrane compartments (supplemental Fig. S7, C
andD). Consistentwith the ultrastructural study, a simple cellular
fractionation of FBS and oleate-treated cells showed that inhibi-
tion of cPLA2 promoted re-distribution of TAG from a cytosol-
enriched to amembrane-enriched fraction (Fig. 8, I–L).
FIGURE 6. cPLA2 is not involved in the synthesis of neutral lipids during LDbiogenesis.A, serum-starved
CHO-K1 cells were exposed for 6 h to 10 M AA or to 100 M AA in combination with 7.5% FBS, and phospho-
Ser505-cPLA2 and ADRP were detected by Western blot. B, serum-starved CHO-K1 cells were labeled 24 h with
[3H]AA and then treated for 6 h with 10 M AA or with 100 M AA in combination with 7.5% FBS and in the
presence or absence of 10 M MAFP. These same treatments were used to quantify the occurrence of LD by
flow cytometry (C and D). C shows the event distribution profiles in FL1 of a representative experiment,
whereas the means S.E. of the median values of three event distributions are shown in D. E, serum-starved
CHO-K1 cells were prelabeled 24 hwith [3H]AA and treated for 6 hwith 7.5% FBS in the absence or presence 10
MMAFP. Radioactivity in TAG (left) and cholesteryl esters (center) was comparedwith radioactivity released to
the medium, indicative of cPLA2 activity (right). *, significantly different (p 0.01) from serum-starved condi-
tions; #, significantly different (p 0.01) from serum plus AA conditions.
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MAFP Inhibits LD Biogenesis in all Cell Types Tested—Fi-
nally, we tested in other cell types the protocol of LD induction
by FBS during 6 h and the reversion of this response by MAFP
(Table 1). LD content decreased in all cells upon serum with-
drawal for 24 h (not shown). Addition of FBS increased LD-
associated fluorescence of Nile red in all cells, and this was
sensitive to inhibition by MAFP. Of particular interest is the
comparison among the LD occurrence in HEK cells and HEK
stably transfected with EGFP-cPLA2 (HEK-cPLA2), where the
latter showed a general increase in LD occurrence either in
serum-starved or FBS-stimulated conditions, consistent with
data onCHO-cPLA2 cells (Fig. 4,D and E). Also, transfection of
siRNA(1) and also of siRNA(2), the latter without effect in Chi-
nese hamster ovary cells, decreased cPLA2 expression (not
shown) and LD in human SH5YSY cells (Table 1). Taken
together, and considering the ubiquitous expression of cPLA2
in mammalian tissues (47), the results suggest a general impli-
cation of the enzyme in LD biogenesis.
DISCUSSION
An important drawback in the study of LD is the limited
choice of quantitative methods. Reliable quantification of LD
visualized in cells stainedwith lipophilic dyes has been reported
after thorough analysis of droplet and cell dimensions (13) or a
careful image treatment (28). There has been a limited use of
flow cytometry, however, for quantification purposes. Nile red
is a lipophilic dye widely used in the study of LD, with an emis-
sion spectrum that shifts to shorter wavelengths in hydropho-
bic environments.When Nile red-stained cells are examined at
wavelengths of 580 nm or less, the fluorescence of the probe
interactingwith the extremely hydrophobic environment of LD
ismaximized, whereas that of cellularmembranes isminimized
(50, 51). This makes Nile red a suitable probe for indirect quan-
tification of LD by flow cytometry (32). In fact, fluorescence
intensities of the event distributions have shown a close agree-
ment with LD under microscopic examination and with NMR
signals (52). A similar indirect quantification of LD by flow
cytometry in BODIPY-stained D3922 cells undergoing apopto-
sis has been reported (53). This technique offers the advantage
of a rapid analysis of multiple samples each consisting of thou-
sands of cells. Also, Nile red staining of the cells does not
require treatment with organic solvents that could extract LD
content and alter their size and shape (2, 54). Furthermore, in
contrast with microscopy, flow cytometry does not involve the
need of washing out excess dye that could result in its re-distri-
bution under nonequilibrium conditions.
When considering the putative role of cPLA2, it is impor-
tant to bear in mind that the enzyme could work after the gen-
eration of eicosanoids that in turn might modify signal trans-
duction pathways, or directly affect membrane function after
the generation of lysophospholipids or free fatty acids (36), or
simply provide fatty acids for the generation of TAG or cho-
lesteryl esters, themain lipids contained in LD. Induction of LD
with lipoproteins present in FBS or with exogenous fatty acids
FIGURE 7. cPLA2 is not required for the channeling of fatty acids from the
mediumintoLD.A–C, serum-starvedCHO-K1cellswere incubated for6hwith2
Ci/ml [3H]AA alone (A), which yielded a final AA concentration of 10 nM, or
together with 1 M (B) or 10 M unlabeled AA (C), in the absence (open bars) or
presenceof10MMAFP(filledbars).1or10MunlabeledAAreducedthespecific
activity of the tracer to 2 or 0.2 Ci/mmol, respectively. Lipids were extracted and
separated by TLC. Results are expressed in pmol of AA incorporated into the
major lipid species: PL, phospholipids; DAG, diacylglycerol; FA, fatty acids; TAG,
triglycerides; CE, cholesteryl esters. *, different from control (p  0.05); #, not
different fromcontrol (p0.05).DandE,ChinesehamsterovaryK1cellswere left
untreated (lanes 4 and 5) or treated 10 hwith 7.5%FBS plus 100Moleate in the
absence (lanes 6 and 7) or presence of 10 M MAFP (lanes 8 and 9). Lipids were
extracted, separated in TLC, and stainedwith primuline spray (D). Lanes 1–3 con-
tain 1, 5, and10g tripalmitine, respectively. E represents densitometry quantifi-
cationofprimuline-stainedTAG(gofTAG in2105 cells), andaremeans range
of two independent experiments with duplicate determinations. **, different
from serum-starved conditions (p 0.05); ##, not different from FBS oleate
(p 0.05).
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(arachidonate, oleate, and palmitate) can be regarded as a sim-
ple channeling of material into neutral lipids that are stored in
LD, and therefore the role of cPLA2 in LD biogenesis is less
obvious thanmerely providingAA for neutral lipid synthesis. In
contrast to fatty acids, lipoproteins are internalized by recep-
tor-mediated endocytosis, and in this regard a BEL-sensitive
PLA2has been found required for vesicle fusion (55) and sorting
(56) along the endocytic pathway, an effect that may be mim-
icked by exogenous AA supplementation. Clearly this is not the
present case, because (a) we show that BEL is not effective to
block LD biogenesis; and (b) more importantly, fatty acids in
the absence of lipoproteins also promote LD appearance. These
observations strongly argue against a link between cPLA2 and
LD biogenesis involving lipoprotein metabolism.
Group VI PLA2 (iPLA2) was our best candidate in initial
experiments, because it is involved in membrane traffic events
other than the endocytic pathway, including retrograde mem-
brane movement from the Golgi apparatus to the ER (56) or
phagosome formation (57). However, although AACOCF3 and
MAFP inhibit cPLA2 and iPLA2, BEL is selective for iPLA2 and
had no effect on LD biogenesis. In contrast to iPLA2, cPLA2 is
considered the key enzyme mediating AA release for the pro-
duction of eicosanoids (38). As mentioned earlier, LD develop
in cells associated with inflammation, and it has been suggested
that LD may be a source for inflammatory precursors (17). In
this regard, we have found that cyclooxygenase inhibitors (20
M indomethacin or 500M ibuprofen) are unable tomimic the
effect of cPLA2 inhibitors in blocking the biogenesis of LD
induced by FBS,6 suggesting that, although LD may serve as an
AA-rich reservoir for the initiation of inflammatory cascades,
eicosanoid production is not involved in their biogenesis. This
is in keeping with Bozza et al. (17), who showed that, although
aspirin inhibited fatty acid-induced LD formation, this effect
was independent of COX inhibition.We also took into account
the possibility that AA generated by cPLA2 could act as a ligand
for peroxisome proliferator-activated receptor- and mediate
lipogenesis and LD formation (58). Again, we found that treat-
ment with the peroxisome proliferator-activated receptor-
agonist pioglitazone at 50 M did not induce LD over a 6-h
treatment nor did it potentiate the effect of FBS; also the antag-
onist GW9662 at 10 M had no effect.6 Long-chain polyunsat-
urated fatty acids have been shown to regulate ADRP expres-
sion (59), and therefore the role of cPLA2could be to promote
ADRP expression after the generation of AA. We have shown,
however, that addition of exogenous AA, which by itself
induced LD, did not restore LD biogenesis either in MAFP-
treated cells or after knocking downcPLA2 expression. There-
6 A. Gubern and E. Claro, unpublished observations.FIGURE 8. Precluding LD formation by the inhibition of cPLA2 alters the
structure of the endoplasmic reticulum and re-distributes TAG from
cytosolic to membrane compartments. A–D, serum-starved Chinese hamster
ovary K1 cells were treated for 6 h with 7.5% FBS and 1 M C1-BODIPY 500/510
C12, in the absence (A and B) or presence of 10 M MAFP (C and D), fixed in
paraformaldehyde, and visualized in the confocal microscope. Scale bars are as
follows:A andC,47.62m;B, 12.42m;D, 27.31m. E–H, cellswere treated10h
with 7.5% FBS plus 100M oleate in the absence (E and F) or presence of 10M
MAFP (G and H), fixed and processed for electronmicroscopy. N and LD denote
nuclei and lipid droplets, respectively; arrows, smooth ER; arrowheads, abnormal
tubulovesicular structures. Magnification: E, 20,000; F,  80,000;
G,12,000;H,40,000. I–L, serum-starvedcellswere left untreatedor treated
10 hwith 7.5% FBS plus 100Moleate, andwith orwithout 10MMAFP, then
homogenized and centrifuged 1 h at 20,000 g to obtain pellet and super-
natant fractions, denoted as P and S, respectively. I shows a representative
Western blot of 15g of protein from P and S fractions, which were enriched
in flotillin-1 and GAPDH, respectively. Cntrl, control. TAG from both fractions
were separatedbyTLC (J) andquantified (K).n.s., not significant.MAFPdidnot
affect total TAG content (K), but induced a re-distribution of TAG from super-
natant (L, open bars) to the pellet fraction (L, solid bars). Lanes 1–3 in J corre-
spond to 1, 5, and 10 g of tripalmitine standard. Asterisks in L denote the
significant (p 0.001) effect of MAFP on TAG distribution among pellet and
supernatant fractions.
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fore, the role of cPLA2 in the biogenesis of LD induced either
by lipoproteins present in serum, fatty acids at subtoxic concen-
trations, or the combination of serum and higher fatty acid
concentrations does not seem related to the generation of AA
or its metabolites.
Our results reveal that TAG and cholesteryl ester synthesis
can be dissociated from LD occurrence, because we found no
MAFP-sensitive difference in [3H]AA incorporation into these
lipid species under LD-forming and nonforming conditions.
The ability to synthesize TAG, together with the incapacity to
form LD, is most probably the basis for the altered smooth ER
structure. This situation is clearly different from the inhibition
of acyl-CoA synthetase with triacsin C, which abolishes LD for-
mation together with that of TAG and cholesteryl esters (15).
Interestingly, Nile red fluorescence was able to discriminate
ER- from LD-associated TAG. We found that triacsin C pre-
cluded LD formation in FBS- and FBS plus oleate-treated cells,
and this effect was similar to that of MAFP in terms of Nile red
fluorescence profiles. As cPLA2 inhibition does not affect
TAG synthesis, this indicates that the hydrophobicity of
excess TAG accumulating in the ER is closer to that of mem-
branes than that of LD. Keeping this inmind, our finding that
inhibition of cPLA2 decreases ADRP content fits with the
observation of Wolins et al. (60), who found that in oleate-
loaded adipocytes ADRP moves to already formed nascent LD
coated with S3-12. Therefore, the role of cPLA2 in LD biogen-
esis would fit somewhere between the synthesis of TAG and
cholesteryl esters and the generation of nascent LD. It could be
required to allow the formation of primordial, nascent LD from
the ER. Alternatively, it might favor fusion events between
newly formed LD, which have been shown to increase in size
independently of TAG synthesis (61), and may not be detecta-
ble either by epifluorescencemicroscopy, by flow cytometry, or
by NMR, as proposed recently (13). The latter possibility, how-
ever, does not quite fit our results, as it is difficult to envisage
how inhibiting fusion of micro-LD would induce the marked
alterations in ER structure revealed by electron microscopy.
Either way, the elucidation of the precise role of cPLA2 in
these processes awaits further investigation. Bothmechanisms,
droplet formation from the ER and fusion of already formed
ones, would be favored by PLA2-generated lysophospholipids,
because of their inverted cone shape that may drive the forma-
tion of positive membrane curvature (36, 62). A similar mech-
anism has been proposed for the calcium-dependent, MAFP-
sensitive PLA2 implicated in Golgi vesiculation induced by
cholesterol (63).
Another question arising is how cPLA2 is activated by
serum lipoproteins or free fatty acids, the two LD-forming con-
ditions used in this study. Regulation of cPLA2 (see Ref. 38 and
references therein) is because of increases in cytosolic calcium
concentrations, which interact with a C2 domain of the protein
and promote its membrane association to access the phospho-
lipid substrate. Besides, phosphorylation on Ser505 plays a rele-
vant role under transient, physiological submicromolar [Ca2],
increasing the phospholipid binding affinity of the enzyme (47),
but it appears less important in response to higher sustained
[Ca2]. Our results show that addition of FBS to serum-starved
cells stimulates cPLA2 in a manner that requires phosphoryl-
ation on Ser505, and we have obtained pharmacological and
molecular evidence showing that this event involves c-Jun
kinase.7 This aspect may have been overlooked before, as most
studies are done in cells maintained in complete medium, and
conceivably phosphorylation is already present in control con-
ditions. Future efforts to address what role [Ca2] and perhaps
signaling lipids like phosphatidylinositol 4,5-bisphosphate (40,
64) and ceramide 1-phosphate (65) play in cPLA2 activation,
and also what are the upstream events leading to cPLA2 phos-
phorylation, will contribute to clarifying themechanisms of LD
biogenesis.
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